GlassScriptPhysician profile
Bianca Jenkins
NPI 1568099380
$5,741.95
in general payments reported to CMS, 2019-2025
27 companies · $2,689 in 2025
The $2,689 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $141 · 2023: $911 · 2024: $2,001 · 2025: $2,689.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,568 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,568.48 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $2,057.69 | 2023-2025 | Dovato, Apretude, Cabenuva |
| Gilead Sciences, INC. | $1,461.40 | 2023-2025 | Yeztugo, Biktarvy |
| Merck Sharp & Dohme LLC | $488.70 | 2023-2025 | Pifeltro, Delstrigo, Capvaxive |
| Theratechnologies INC. | $305.77 | 2023-2025 | Trogarzo, Egrifta |
| Abiomed | $303.20 | 2022-2023 | Impella |
| Novo Nordisk INC | $248.17 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $165.46 | 2025 | Repatha, Otezla |
| Napo Pharmaceuticals INC | $111.94 | 2023-2025 | Mytesi |
| Abbvie INC. | $87.87 | 2024-2025 | |
| Exact Sciences Corporation | $62.84 | 2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $53.71 | 2023-2025 | Bexsero, Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $41.05 | 2025 | Rexulti |
| Lilly USA, LLC | $39.07 | 2025 | Mounjaro, Zepbound |
| Dynavax Technologies Corporation | $38.30 | 2024-2025 | Heplisav-B |
| Emd Serono, INC. | $34.29 | 2023-2025 | Serostim |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $28.59 | 2025 | Flucelvax, Fluad |
| Pfizer INC. | $27.27 | 2024 | |
| Inspire Medical Systems, INC. | $25.00 | 2025 | Inspire |
| Indivior INC. | $24.11 | 2025 | Sublocade |
| Janssen Biotech, INC. | $23.25 | 2023 | Symtuza |
| Cranial Technologies, INC | $21.04 | 2024 | Doc Band |
| Teva Pharmaceuticals USA, INC. | $18.11 | 2023 | Austedo Xr |
| Coopersurgical, INC. | $16.96 | 2023 | Paragard T 380a |
| Halozyme INC | $15.90 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.01 | 2025 | Caplyta |
| Braeburn INC. | $13.93 | 2025 | Brixadi |
| Edwards Lifesciences Corporation | $13.32 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bianca Jenkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.